These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

338 related articles for article (PubMed ID: 38016356)

  • 21. Oxaliplatin-loaded nanoemulsion containing
    Al-Otaibi WA; AlMotwaa SM
    Drug Deliv; 2022 Dec; 29(1):2190-2205. PubMed ID: 35815706
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The bioengineered and multifunctional nanoparticles in pancreatic cancer therapy: Bioresponisive nanostructures, phototherapy and targeted drug delivery.
    Saadh MJ; Baher H; Li Y; Chaitanya M; Arias-Gonzáles JL; Allela OQB; Mahdi MH; Carlos Cotrina-Aliaga J; Lakshmaiya N; Ahjel S; Amin AH; Gilmer Rosales Rojas G; Ameen F; Ahsan M; Akhavan-Sigari R
    Environ Res; 2023 Sep; 233():116490. PubMed ID: 37354932
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The Role of Cyanidin-3-
    Kurter H; Basbinar Y; Ellidokuz H; Calibasi-Kocal G
    Nutrients; 2023 Nov; 15(22):. PubMed ID: 38004099
    [TBL] [Abstract][Full Text] [Related]  

  • 24. (Nano)platforms in bladder cancer therapy: Challenges and opportunities.
    Ashrafizadeh M; Zarrabi A; Karimi-Maleh H; Taheriazam A; Mirzaei S; Hashemi M; Hushmandi K; Makvandi P; Nazarzadeh Zare E; Sharifi E; Goel A; Wang L; Ren J; Nuri Ertas Y; Kumar AP; Wang Y; Rabiee N; Sethi G; Ma Z
    Bioeng Transl Med; 2023 Jan; 8(1):e10353. PubMed ID: 36684065
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effective Delivery of siRNA-Loaded Nanoparticles for Overcoming Oxaliplatin Resistance in Colorectal Cancer.
    Zhou Y; Zhang Q; Wang M; Huang C; Yao X
    Front Oncol; 2022; 12():827891. PubMed ID: 35265524
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Oxaliplatin-Biomimetic Magnetic Nanoparticle Assemblies for Colon Cancer-Targeted Chemotherapy: An In Vitro Study.
    Jabalera Y; Garcia-Pinel B; Ortiz R; Iglesias G; Cabeza L; Prados J; Jimenez-Lopez C; Melguizo C
    Pharmaceutics; 2019 Aug; 11(8):. PubMed ID: 31390773
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The efficacy and side effects of rigosertib combined with chemotherapy in
    Zhang HC; Zhou XY; Fu DL; Ding YW; Xiao Q; Yuan Y
    Zhonghua Zhong Liu Za Zhi; 2023 Feb; 45(2):138-145. PubMed ID: 36781234
    [No Abstract]   [Full Text] [Related]  

  • 28. Bioresponsive and multifunctional cyclodextrin-based non-viral nanocomplexes in cancer therapy: Building foundations for gene and drug delivery, immunotherapy and bioimaging.
    Lu Q
    Environ Res; 2023 Oct; 234():116507. PubMed ID: 37364628
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Synergistic chemotherapy and phototherapy based on red blood cell biomimetic nanomaterials.
    Meng D; Yang S; Yang Y; Zhang L; Cui L
    J Control Release; 2022 Dec; 352():146-162. PubMed ID: 36252749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis.
    Hsu HH; Chen MC; Baskaran R; Lin YM; Day CH; Lin YJ; Tu CC; Vijaya Padma V; Kuo WW; Huang CY
    J Cell Physiol; 2018 Jul; 233(7):5458-5467. PubMed ID: 29247488
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Annexin A1 induces oxaliplatin resistance of gastric cancer through autophagy by targeting PI3K/AKT/mTOR.
    Ren J; Hu Z; Niu G; Xia J; Wang X; Hong R; Gu J; Wang D; Ke C
    FASEB J; 2023 Mar; 37(3):e22790. PubMed ID: 36786694
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Puerarin inhibits EMT induced by oxaliplatin
    Chen X; Zhou Z; Zhang Z; Zhao C; Li J; Jiang J; Huang B; Qin Y
    Front Pharmacol; 2022; 13():969422. PubMed ID: 36091779
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hyaluronic acid oligosaccharide-modified zeolitic imidazolate framework-8 nanoparticles loaded with oxaliplatin as a targeted drug-delivery system for colorectal cancer therapy.
    Li B; Zhang Z; He S; Du W; Yang X; Kou B; Jiang Y; Bian P; Yin L
    Nanomedicine (Lond); 2023 May; 18(12):891-905. PubMed ID: 37409459
    [No Abstract]   [Full Text] [Related]  

  • 34. Controllable Regulation of Ag
    He M; Cheng Z; Wang Z; Li M; Liang H; Liu H; Yu L; Zhao L; Yu F
    Adv Healthc Mater; 2023 Oct; 12(25):e2300752. PubMed ID: 37306666
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin derived monofunctional triazole-containing platinum(II) complex counteracts oxaliplatin-induced drug resistance in colorectal cancer.
    Li Y; Sun Z; Cui Y; Zhang H; Zhang S; Wang X; Liu S; Gao Q
    Bioorg Chem; 2021 Feb; 107():104636. PubMed ID: 33465670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Novel Pt(IV) prodrug self-assembled nanoparticles with enhanced blood circulation stability and improved antitumor capacity of oxaliplatin for cancer therapy.
    Fu Y; Kong Y; Li X; Cheng D; Hou Y; Li Y; Li T; Xiao Y; Zhang Q; Rong R
    Drug Deliv; 2023 Dec; 30(1):2171158. PubMed ID: 36744299
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chemoimmunotherapy by combining oxaliplatin with immune checkpoint blockades reduced tumor burden in colorectal cancer animal model.
    Wang W; Wu L; Zhang J; Wu H; Han E; Guo Q
    Biochem Biophys Res Commun; 2017 May; 487(1):1-7. PubMed ID: 28042031
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A novel estrogen-targeted PEGylated liposome co-delivery oxaliplatin and paclitaxel for the treatment of ovarian cancer.
    Xie Y; Ren Z; Chen H; Tang H; Zhu M; Lv Z; Bao H; Zhang Y; Liu R; Shen Y; Zheng Y; Miao D; Guo X; Chen H; Wang S; Pei J
    Biomed Pharmacother; 2023 Apr; 160():114304. PubMed ID: 36724638
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Doxorubicin-loaded micelles in tumor cell-specific chemotherapy.
    Almajidi YQ; Kadhim MM; Alsaikhan F; Turki Jalil A; Hassan Sayyid N; Alexis Ramírez-Coronel A; Hassan Jawhar Z; Gupta J; Nabavi N; Yu W; Ertas YN
    Environ Res; 2023 Jun; 227():115722. PubMed ID: 36948284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. RecQ-like helicase 4 (RECQL4) exacerbates resistance to oxaliplatin in colon adenocarcinoma via activation of the PI3K/AKT signaling pathway.
    Zhou F; Wang L; Jin K; Wu Y
    Bioengineered; 2021 Dec; 12(1):5859-5869. PubMed ID: 34477047
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.